ARA-290 (Cibinetide): The Nerve Repair Protocol
Disclaimer: This article is for educational and research purposes only. ARA-290 is a synthetic peptide derived from erythropoietin (EPO) and is currently in Phase 2 clinical trials. It is not approved by the FDA for human use. Information reflects current 2024–2026 clinical research data.
What is ARA-290?
ARA-290 (also known as Cibinetide) is a synthetic 11-amino acid peptide engineered from the structure of erythropoietin (EPO). However, it is non-erythropoietic, meaning it does not stimulate red blood cell production or increase the risk of blood clots—a common side effect of full-length EPO.
Its primary role in research is the activation of the Innate Repair Receptor (IRR). This receptor is only "turned on" during tissue injury or inflammation, making ARA-290 a highly targeted "emergency response" peptide for nerve damage and chronic inflammatory states.
- Molecular Formula: $C_{51}H_{84}N_{16}O_{21}$
- Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Primary Target: Innate Repair Receptor (IRR) / CD131
Mechanism of Action
ARA-290 works as a "molecular switch" for tissue protection:
- Selective Binding: It binds to the heterocomplex of the EPO receptor and the$\beta$-common receptor (CD131).
- Anti-Inflammatory Signaling: It shuts down the production of pro-inflammatory cytokines like TNF-$\alpha$ and IL-6.
- Neuro-Regeneration: Clinical trials have shown it can actually increase corneal nerve fiber density, suggesting it doesn't just mask pain but facilitates the physical regrowth of small nerve fibers.
Current Research Landscape (2024–2026)
Key Study Findings
| Focus Area | Primary Outcome | Reference |
| Small Fiber Neuropathy | Significant reduction in pain scores and increased nerve density. | NEJM / ClinicalTrials.gov (2025) |
| Sarcoidosis | Improved physical functioning and reduced fatigue in 28-day cycles. | Leiden University Study |
| Type 2 Diabetes | Improved HbA1c and lipid profiles alongside neuropathy relief. | Diabetes Care (2024) |
Research Protocols (10mg Vial)
In clinical settings (such as the sarcoidosis trials), ARA-290 is typically administered daily for a specific block of time to "reset" the inflammatory environment.
Reconstitution (2 mL BAC Water)
For a 10 mg vial, adding 2 mL of Bacteriostatic Water (BAC) provides an accurate concentration for standard milligram dosing.
Total Vial: 10 mg (10,000 mcg)
Concentration: 5 mg per 1 mL (50 mcg per unit)
Dosing Schedule
| Research Level | Daily Dose | Syringe Units (IU) | Duration |
| Low Dose | 1 mg | 20 Units | 28 Days |
| Standard Clinical | 4 mg | 80 Units | 28 Days |
| High Dose | 8 mg | 160 Units (2 shots) | 28 Days |
Protocol Note: Most successful human trials used 4 mg daily for 28 consecutive days. After 28 days, a "washout" period of 30 days is often observed to assess the long-term regenerative effects.
Frequently Asked Questions
Does it cause the "EPO blood-thickening" effect?
No. ARA-290 was specifically designed to exclude the hematopoietic domain of EPO. It has no effect on hemoglobin or hematocrit levels in clinical trials.
How fast does it work?
While the anti-inflammatory effect is rapid, nerve regeneration is a slow process. Researchers typically observe significant pain reduction starting at Day 14, with maximum benefits appearing after the full 28-day cycle.
When should it be administered?
ARA-290 has a very short half-life (~20 minutes in plasma), but its "switch-flipping" effect on receptors lasts much longer. It can be administered at any time of day, though consistency is key.
Is it stable after reconstitution?
ARA-290 is relatively stable but sensitive to heat. It must be refrigerated (2-8°C) and used within 28 days of reconstitution.
Summary Checklist
- [ ] 1 Vial ARA-290 (10 mg).
- [ ] 2 mL Bacteriostatic Water.
- [ ] Subcutaneous injection (typically stomach or thigh).
- [ ] Storage: Refrigerator only.